Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses.
Matthew Steven Davids
No relevant relationships to disclose
John Francis Seymour
Consultant or Advisory Role - AbbVie; Roche/Genentech
Research Funding - AbbVie; Genentech
John F. Gerecitano
Research Funding - AbbVie; Genentech
Brad S. Kahl
Consultant or Advisory Role - Genentech
Research Funding - AbbVie; Genentech
John M. Pagel
No relevant relationships to disclose
William G. Wierda
Consultant or Advisory Role - Roche/Genentech
Research Funding - AbbVie; Genentech
Mary Ann Anderson
Research Funding - AbbVie; Genentech
Nikita Rudersdorf
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Lori A. Gressick
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Nicholas P. Montalvo
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Jianning Yang
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Ming Zhu
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Martin Dunbar
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Elisa Cerri
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Sari H. Enschede
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Rod Humerickhouse
Employment or Leadership Position - AbbVie
Stock Ownership - AbbVie
Andrew Warwick Roberts
Research Funding - AbbVie; Genentech